Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Incidence of drug-induced liver injury 

A study in the latest issue of Gastroenterology examines the incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

News image

Little is known about the incidence of drug-induced liver injury in the general population.

Dr Einar Björnsson and colleagues from Iceland investigated the incidence, and the quantitative risk of drug-induced liver injury in a population-based cohort.

The research team performed a prospective study and collected data from 96 individuals diagnosed with drug-induced liver injury in Iceland from 2010 through 2011.

Liver injury was defined based on levels of alanine aminotransferase that were more than 3-fold the upper limit of normal, and/or alkaline phosphatase levels more than 2-fold the upper limit of normal.

Patients with acetaminophen toxicity were excluded.

The research team analyzed the drug history and clinical outcomes.

Drug-induced liver injury was caused by a single prescription medication in 75% of cases
Gastroenterology

Causality was assessed using the Roussel Uclaf Causality Assessment Method.

The patients were registered in prescription databases for outpatients and inpatients.

The crude annual incidence rate of drug-induced liver injury was 19 cases per 100,000 inhabitants.

The doctors found that drug-induced liver injury was caused by a single prescription medication in 75% of cases, by dietary supplements in 16% of cases, and by multiple agents in 9% of cases.

The most commonly implicated drugs were amoxicillin-clavulanate, diclofenac, azathioprine, infliximab, and nitrofurantoin.

The median duration of therapy was 20 days.

The team observed that 26 patients had jaundice, and 22 patients were hospitalized for a median of 5 days.

The researchers noted that overall 35,252 patients received amoxicillin-clavulanate as outpatients, and drug-induced liver injury occurred in 1 of 2350.

Drug-induced liver injury also occurred in 1 of 9480 patients taking diclofenac, 1 of 133 patients taking azathioprine, 1 of 148 patients taking infliximab, and 1 of 1369 patients taking nitrofurantoin.

Dr Björnsson's team commented, "In a population-based study in Iceland, the incidence of drug-induced liver injury was the highest reported to date."

"Amoxicillin-clavulanate was the most commonly implicated agent."

"The highest risk of hepatotoxicity was associated with azathioprine and infliximab, but the actual number of cases attributed to these agents was small."

Gastroenterol 2013: 144(7) :1419-1425
04 July 2013

Go to top of page Email this page Email this page to a colleague

 05 March 2015

Advanced search
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 04 March 2015 
Management of IBD
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
Risk of anastomotic leak after colectomy
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us